Health Care Services

UNI MEDICAL

Universal Healthcare Revenue Down 4.5% Q1, Profit Up 5.2%

China Global Leasing Limited Completes Issue of RMB 500 Million Corporate Bonds

CCL Completes RMB 500 Million Medium-Term Note Issuance

China Universal Healthcare's Wholly Owned Subsidiary Issuing RMB 500 Million Medium-term Notes

CUGL Approved to Issue RMB 1 Billion in Public Corporate Bonds

UNI MEDICAL released FY2025 9 Months earnings on March 25 (BJT), actual revenue HKD 11.97 B, actual EPS HKD 0.9249

UNI MEDICAL released FY2025 Q3 earnings on March 25, 2026 (BJT) with actual revenue of HKD 0 and EPS of HKD 0

UNI MEDICAL released FY2025 Q4 earnings on March 25 During-Market (BJT), actual revenue HKD 3.913 B, actual EPS HKD 0.2573

UNI MEDICAL released FY2025 Annual Earnings on March 25 During-Market (BJT), actual revenue HKD 15.89 B (forecast HKD 16.26 B), actual EPS HKD 1.1831 (forecast HKD 1.2454)

UNI MEDICAL to release FY2025 earnings on March 25 During-Market BJT, forecast revenue HKD 16.34 B, EPS HKD 1.2243

China Universal Healthcare's Wholly-Owned Subsidiary Issues RMB 1 Billion Corporate Bond

Citic Medical's subsidiary approved to issue RMB 8 billion corporate bonds

Universal Healthcare Forms Joint Venture with China New Energy and Helletech to Accelerate Innovation Medical Devices

Universal Healthcare Subsidiary Completes RMB 200 Million Bond Issuance

Huanqiu Medical Reports Double Growth in Revenue and Profit for First Nine Months of 2025

UNI MEDICAL released FY2025 Q1 earnings on August 27 (BJT), actual revenue HKD 4.017 B, actual EPS HKD 0.332

UNI MEDICAL released FY2025 Q2 earnings on August 27 Pre-Market (BJT), actual revenue HKD 4.105 B, actual EPS HKD 0.3396

UNI MEDICAL released FY2025 Semi-Annual earnings on August 27 Pre-Market (BJT), actual revenue HKD 8.122 B, actual EPS HKD 0.6719

UNI MEDICAL to release FY2025 Semi-Annual earnings report on August 27, 2025 (BJT)

Huaron Medical Announces Final Dividend of HKD0.35 Per Share

I.CENTURY HLDG

RIVERINE CHINA

KOS TALENT GP

CHINA CBS INTL

NATURE ENERGY T

DIGIT HOLLYWOOD

REDCO HEALTHY

ZXZN QI-HOUSE

ASIA PIONEER

HUISHENG INTL

02666

Genertec Universal Medical Group Company has announced a delay in dispatching a circular to shareholders regarding the revised annual cap for 2026 under its Medical Related Product Procurement Framework Agreement. The new dispatch date is set for on or before 9 June 2026, instead of the previously indicated 19 May 2026. This delay is for administrative reasons and does not affect the underlying proposal.

Tip Ranks

Genertec Universal Medical delays dispatch of circular on revised procurement cap

Genertec Universal Medical Group (SEHK:2666) reported full year 2025 earnings with a net income of CN¥2,208.95m and basic earnings per share of CN¥1.13. Following the earnings release, the share price rose by 2.41% to HK$5.95, but the stock has seen a 3.41% decline over the past 90 days. The company's P/E ratio stands at 4.8x, significantly lower than the industry average of 10.9x, indicating potential undervaluation. A DCF model suggests a fair value of HK$9.23 per share, highlighting a 35.5% discount. Investors are encouraged to assess risks and opportunities in the healthcare sector.

Simplywall

Evaluating Genertec Universal Medical Group’s Valuation After Its Latest Earnings And Share Price Reaction

516610

Genertec Universal Medical Sets Out Board and Committee Structure

Dacheng CSI All Share Health Care Equipment and Services ETF

Genertec Universal Medical Sets Out Board and Committee Structure

According to a report from Economic Information Daily on the 6th, UNI MEDICAL announced that its subsidiary, General Universal International Financing Leasing (Tianjin) Co., Ltd., has decided to issue domestic medium-term notes in the first phase of 2025 with a total principal amount of up to RMB 200 million to institutional investors within China. The related net proceeds will be used by the issuer to repay maturing debts. (rh)

etnet

UNI MEDICAL issues up to 200 million yuan in medium-term notes

Pacific Securities maintains a "Buy" rating on UNI MEDICAL, with a target price of HKD 7.97. It is expected that the operating revenues for 2025-2027 will be 14.723 billion, 15.343 billion, and 16.254 billion yuan, respectively, with net profits attributable to the parent company of 2.118 billion, 2.228 billion, and 2.366 billion yuan. The healthcare business has become the core growth engine, with revenue of 4.964 billion yuan in the first half of 2025, a year-on-year increase of 27.7%. The financial business is stable, with sufficient risk resistance capability

Zhitong

Pacific Securities: Maintain "Buy" rating on UNI MEDICAL with a target price of HKD 7.97

UNI MEDICAL(02666.HK)

Genertec Universal Medical delays dispatch of circular on revised procurement cap

Evaluating Genertec Universal Medical Group’s Valuation After Its Latest Earnings And Share Price Reaction

Genertec Universal Medical Sets Out Board and Committee Structure

UNI MEDICAL issues up to 200 million yuan in medium-term notes

Pacific Securities: Maintain "Buy" rating on UNI MEDICAL with a target price of HKD 7.97